ArticleScientific reports2026
Development of a model to predict nicotine pharmacokinetics from oral nicotine pouches.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral Nicotine Pouches (ONPs) have emerged as a promising non-combustible nicotine alternative to traditional tobacco products. Regulatory approval of ONPs in the United States requires comprehensive studies to demonstrate that new tobacco products are appropriate for the protection of public health. Conventional nicotine pharmacokinetic (PK) studies typically depend on expensive and time-intensive human trials. To address this challenge, a predictive PK model to forecast buccal absorption of nicotine from ONPs was developed using in vitro data. A novel dissolution method employing a µDISS Profiler was used to generate nicotine dissolution and dynamic pH profiles for three commercially available ONPs: ZYN Cool Mint 6 mg, DRYFT Spearmint 7 mg, and VELO Mint 4 mg. The model integrates experimental in vitro data with established nicotine PK parameters to predict clinical PK profiles. It effectively forecasted key PK metrics, including AUC, C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.